Article Text

PDF
Rituximab and ▼abatacept for rheumatoid arthritis
  • Relevant BNF section: 10.1.3

Abstract

Estimates from the UK indicate that around 0.5–1.0% of the population have rheumatoid arthritis.1 Here we assess the place of rituximab (MabThera – Roche Products Ltd) and ▼abatacept (Orencia – Bristol-Myers-Squibb), drugs in two new classes, which are licensed for certain adults with the condition.

Statistics from Altmetric.com

  • Relevant BNF section: 10.1.3

View Full Text

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.